January 2024

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis)

Rheumatol Ther 2023;11(1):177–189 doi 10.1007/s40744-023-00619-0

This post hoc analysis by Curtis, et al. found that current and former smokers were more likely to switch from an anti-TNF bDMARD to a different bDMARD or JAK inhibitor in comparison to non-smokers. They also found that DAS28(CRP) ≤3.2 achievement was significantly higher after filgotinib therapy regardless of smoking status in MTX-IR, bDMARD-IR, and MTX-naïve patients.

Keywords:

December 2023

MACE e VTE nos programas de ensaios clínicos de upadacitinibe em artrite reumatoide, artrite psoriática e espondilite anquilosante

RMD Open 2023; 9(4):e003392 doi 10.1136/rmdopen-2023-003392

Rates of MACE and VTE events in patients with RA or PsA treated are consistent across 15 mg and 30 mg doses of upadacitinib, and comparable with active comparators adalimumab and MTX. Several risk factors were also identified for MACE and VTE events in patients with RA.

Keywords:

Malignidades nos ensaios clínicos com upadacitinibe em artrite reumatoide, artrite psoriática, espondilite anquilosante e espondiloartrite axial não radiográfica

Rheumatol Ther 2023;11(1):97–112 doi 10.1007/s40744-023-00621-6

Rates of malignancy were similar between upadacitinib, adalimumab, and MTX. They were also consistent across RA, PsA, AS and nr-axSpA. A dose-dependent increased rate of NMSC was observed with upadacitinib in RA. For RA and PsA, being older (≥65 years) and male was associated with
an increased risk of malignancy excluding NMSC.

Keywords:

October 2023

Anti-gm-csf Otilimabe versus Sarilumab ou Placebo em Pacientes com Artrite Reumatoide e Resposta Inadequada a Terapias Direcionadas: Um Estudo Randomizado de Fase III (contRAst 3)

Ann Rheum Dis. 2023;82(12):1527–1537 doi 10.1136/ard-2023-224449

The ContRAst 3 study investigated otilimab, in RA patients with inadequate responses to multiple treatments. Otilimab did not significantly improve ACR20 versus placebo at Weeks 12 or 24. In addition, there we no significant improvements in secondary endpoints, including disease activity, disability, and pain.

Keywords:

Prevenção da progressão radiográfica em pacientes com artrite reumatoide de alto risco usando estudos de fase III com filgotinibe: Revisão Narrativa de Análises Post Hoc

Rheumatol Ther. 2023;10(6):1399–1415 doi: 10.1007/s40744-023-00590-w

Findings from post hoc analyses extend the knowledge base for radiographic benefits of filgotinib in patients with RA.

Keywords:

Anti-GM-CSF Otilimabe versus Tofacitinib ou Placebo em pacientes com artrite reumatoide ativa e resposta inadequada a DMARDs convencionais ou biológicos: Dois Estudos Randomizados de Fase 3 (contRAst 1 e contRAst 2)

Ann Rheum Dis 2023;0:1–11 doi 10.1136/ard-2023-224482

Fleischmann, et al investigated the safety and efficacy of otilimab versus tofacitinib and placebo in RA patients treated with MTX (contRAst 1) or csDMARDs (contRAst 2). They found that while otilimab achieved the primary endpoint of ACR20 versus placebo in Week 12, it did not demonstrate non-inferiority to tofacitinib.

Keywords:

July 2023

Baricitinibe na artrite idiopática juvenil: Um estudo internacional, de fase 3, randomizado, duplo-cego, controlado com placebo, de retirada, eficácia e segurança

Lancet. 2023;402(10401):555–570 doi 10.1016/S0140-6736(23)00921-2

Phase 3 trial of baricitinib demonstrates efficacy with acceptable safety profile in polyarticular and extended oligoarticular juvenile idiopathic arthritis, juvenile psoriatic arthritis and enthesitis-related arthritis.

Keywords:

Análise post hoc em pacientes com artrite reumatoide em remissão clínica em dois estudos japoneses de fase 3 sobre o tratamento com peficitinibe (RAJ3 e RAJ4)

Mod Rheumatol 2023;34(3):453–65 doi: 10.1093/mr/road059

Pots hoc analysis of peficitinib Phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.

Keywords:

Perfil de segurança de upadacitinibe em pacientes com risco cardiovascular: análise post hoc integrada do programa clínico de fase III SELECT na artrite reumatoide

Ann Rheum Dis. 2023 doi: 10.1136/ard-2023-223916

Pots hoc analysis of safety data in patients with RA at increased risk of CV events from the upadacitinib SELECT phase III RA clinical programme helps to contextualise the overall risk profile of upadacitinib.

Keywords:

May 2022

Dois Ensaios de fase 3 de baricitinib para alopecia areata

N Engl J Med. 2022. Epub ahead of print doi: 10.1056/NEJMoa2110343

Phase 3 trials in patients with severe alopecia areata show that baricitinib is superior to placebo with respect to hair regrowth at 36 weeks.
Alopecia areata is characterised by nonscarring hair loss that can affect any hair-bearing site. Although mild cases of this emotionally- and psychosocially-distressing autoimmune disease may resolve within 12 months, more severe forms of the disease are unlikely to remit without treatment.

Keywords: